(Reuters) – Africa’s top public health body plans to talk to Merck about obtaining supplies of its Molnupiravir treatment pill for COVID-19, although talks with Pfizer about its Paxlovid medication were more advanced, it said on Thursday.
“We don’t have a preference to talk only to Pfizer and not Merck, it’s just that Pfizer has been more forthcoming with their engagement. We plan to engage both companies equally,” said John Nkengasong, director of the Africa Centres for Disease Control and Prevention.
(Reporting by Alexander Winning; Writing by Estelle Shirbon; Editing by Alison Williams)
